Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V. Michot JM, et al. Among authors: danu a. Eur J Cancer. 2015 Nov;51(16):2386-95. doi: 10.1016/j.ejca.2015.07.009. Epub 2015 Aug 5. Eur J Cancer. 2015. PMID: 26254810
Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S. Michot JM, et al. Among authors: danu a. Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9. Eur J Cancer. 2017. PMID: 28892775 Review.
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Saleh K, Danu A, Koscielny S, Legoupil C, Pilorge S, Castilla-Llorente C, Ghez D, Lazarovici J, Michot JM, Khalife-Saleh N, Lapierre V, Alenxandrova K, Arfi-Rouche J, Bourhis JH, Ribrag V. Saleh K, et al. Among authors: danu a. Leuk Lymphoma. 2018 Nov;59(11):2580-2587. doi: 10.1080/10428194.2017.1403019. Epub 2017 Nov 22. Leuk Lymphoma. 2018. PMID: 29164977
Investigational drugs for T-cell lymphoma.
Ghez D, Danu A, Ribrag V. Ghez D, et al. Among authors: danu a. Expert Opin Investig Drugs. 2016;25(2):171-81. doi: 10.1517/13543784.2016.1121994. Epub 2015 Dec 17. Expert Opin Investig Drugs. 2016. PMID: 26576861 Review.
Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
Rassy E, Danu A, Ibrahim T, Lazarovici J, Ghez D, Michot JM, Arfi-Rouche J, Rossignol J, Vergé V, Dartigues P, Ribrag V. Rassy E, et al. Among authors: danu a. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e373-e380. doi: 10.1016/j.clml.2020.11.008. Epub 2020 Nov 13. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33277224
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Abdayem P, Ibrahim N, El Dakdouki Y, Willekens C, Ghez D, A Rouche J, Dartigues P, Desmaris R, Danu A, Rossignol J, Lazarovici J, Fermé C, Ribrag V, Michot JM. Abdayem P, et al. Among authors: a rouche j, danu a. Eur J Haematol. 2021 Apr;106(4):574-583. doi: 10.1111/ejh.13589. Epub 2021 Feb 4. Eur J Haematol. 2021. PMID: 33512026
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result.
Michot JM, Annereau M, Danu A, Legoupil C, Bertin L, Chahine C, Achab N, Antosikova A, Cerutti A, Rossignol J, Ghez D, Willekens C, Dartigues P, Lazarovici J, Lemare F, Ribrag V. Michot JM, et al. Among authors: danu a. Eur J Haematol. 2020 Apr;104(4):281-290. doi: 10.1111/ejh.13369. Epub 2020 Jan 28. Eur J Haematol. 2020. PMID: 31838764 Clinical Trial.
115 results